Zymeworks Inc
ZYME22.720USD
+0.700+3.18%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
1.72BCap. mercado
PérdidaP/E TTM
Más Datos de Zymeworks Inc Compañía
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Información de Zymeworks Inc
Símbolo de cotizaciónZYME
Nombre de la empresaZymeworks Inc
Fecha de salida a bolsaJun 24, 2019
Director ejecutivoGalbraith (Kenneth H)
Número de empleados280
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 24
Dirección108 Patriot Drive, Suite A
CiudadMIDDLETOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19709
Teléfono13022748744
Sitio Webhttps://www.zymeworks.com/
Símbolo de cotizaciónZYME
Fecha de salida a bolsaJun 24, 2019
Director ejecutivoGalbraith (Kenneth H)
Ejecutivos de Zymeworks Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Dr. Jeffrey Smith, M.D.
Dr. Jeffrey Smith, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Dr. Jeffrey Smith, M.D.
Dr. Jeffrey Smith, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 1 de feb
Actualizado: dom., 1 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
EcoR1 Capital, LLC
30.69%
Rubric Capital Management LP
6.29%
BVF Partners L.P.
5.26%
Morgan Stanley & Co. LLC
5.23%
Redmile Group, LLC
4.95%
Otro
47.56%
Accionistas
Accionistas
Proporción
EcoR1 Capital, LLC
30.69%
Rubric Capital Management LP
6.29%
BVF Partners L.P.
5.26%
Morgan Stanley & Co. LLC
5.23%
Redmile Group, LLC
4.95%
Otro
47.56%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
51.31%
Investment Advisor
20.98%
Hedge Fund
18.80%
Research Firm
6.53%
Private Equity
2.79%
Individual Investor
1.24%
Venture Capital
0.28%
Sovereign Wealth Fund
0.27%
Pension Fund
0.25%
Participación institucional
Actualizado: mié., 21 de ene
Actualizado: mié., 21 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q4
333
74.80M
105.96%
--
2025Q4
404
76.14M
101.75%
-5.97M
2025Q3
390
74.41M
99.43%
-2.56M
2025Q2
383
76.90M
102.73%
+2.83M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
EcoR1 Capital, LLC
22.97M
30.69%
--
--
Nov 16, 2025
Rubric Capital Management LP
4.71M
6.29%
--
--
Sep 30, 2025
BVF Partners L.P.
3.94M
5.26%
-370.29K
-8.59%
Sep 30, 2025
Morgan Stanley & Co. LLC
3.92M
5.23%
+295.26K
+8.15%
Sep 30, 2025
Redmile Group, LLC
3.71M
4.95%
-444.88K
-10.72%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
4.17%
+11.88K
+0.38%
Sep 30, 2025
The Vanguard Group, Inc.
2.15M
2.87%
-310.26K
-12.63%
Sep 30, 2025
Perceptive Advisors LLC
2.09M
2.79%
+815.39K
+63.94%
Sep 30, 2025
Vestal Point Capital, LP
1.76M
2.36%
+615.00K
+53.48%
Sep 30, 2025
Blackstone Alternative Asset Management, L.P.
1.62M
2.16%
-40.50K
-2.44%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Tema Oncology ETF
2.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.99%
ProShares Ultra Nasdaq Biotechnology
0.24%
iShares Micro-Cap ETF
0.18%
Federated Hermes MDT Small Cap Core ETF
0.15%
WisdomTree US SmallCap Quality Growth Fund
0.15%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.12%
Ver más
Tema Oncology ETF
Proporción2.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.99%
ProShares Ultra Nasdaq Biotechnology
Proporción0.24%
iShares Micro-Cap ETF
Proporción0.18%
Federated Hermes MDT Small Cap Core ETF
Proporción0.15%
WisdomTree US SmallCap Quality Growth Fund
Proporción0.15%
SPDR S&P International Small Cap ETF
Proporción0.14%
Invesco Nasdaq Biotechnology ETF
Proporción0.14%
iShares Biotechnology ETF
Proporción0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.12%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
